Siga falls after FDA says there is no human data supporting co's drug for monkeypox treatment

SIGA Technologies

29/07/2022 20:55

** Smallpox drugmaker Siga Technologies shares fall in
volume spike, now down 25% at $5.6 after FDA says there is no
authorized medicine for the treatment of monkeypox disease
    ** Shares fall after FDA says there is no human data
demonstrating the efficacy of SIGA's drug TPOXX for the
treatment of monkeypox  urn:newsml:reuters.com:*:nL4N2Z61X1 
    ** Monkeypox is a viral infection that causes symptoms
similar to, but milder than, smallpox
    ** FDA says however TPOXX is being made available under its
Expanded Access authorisation, which grants patients access to
an investigational medical product
    ** SIGA has shot up 137.3% this year

 (Reporting by Nandhini Srinivasan in Bengaluru)
 ((Nandhini.srinivasan@thomsonreuters.com))